EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Growth hormone treatment for neurologic symptoms of post‐acute sequelae of COVID‐19

Traver J Wright iD, Melinda Sheffield-Moore iD, Richard B Pyles iD, Kathleen M Randolph iD, Kristen A McGovern iD, Christopher P Danesi iD, Sarah E Lindsay, Mohammed F Zaidan iD, Brent E Masel, Randall J Urban iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Traver J Wright und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Human Growth Hormone, Post-Acute COVID-19 Syndrome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following SARS‐CoV‐2 infection, some patients develop lingering neurologic symptoms of post‐acute sequelae of COVID‐19 (PASC) that commonly include fatigue and “brain fog.” PASC symptoms are also linked with reduced growth hormone (GH) secretion, but GH treatment has not been tested to relieve symptoms. We enrolled 13 adults with neurologic PASC symptoms and peak stimulated GH secretion less than 10 ng/mL (glucagon stimulation) in a pilot study to receive 9 months of daily GH injections and an additional 3 months of off‐treatment assessment. We compared peak stimulated GH secretion at baseline and 12 months and assessed measures of cognition, metabolism, body composition, and physical performance over the first 6 months of treatment. Patient‐reported outcomes of fatigue, quality of life, sleep, and mood were recorded at baseline and compared with timepoints at 6, 9, and 12 months. GH treatment was associated with significantly improved scores for Brief Fatigue Inventory, Multidimensional Fatigue Symptom Inventory, Quality of Life Assessment of Growth Hormone Deficiency in Adults, Profile of Mood States, and Beck Depression Inventory‐II, with no significant change in Pittsburgh Sleep Quality Index. Six months of adjunct GH treatment was not associated with significant changes in cognition, body composition, resting energy expenditure, or physical performance. Peak stimulated GH secretion was not altered at 12 months following 9 months of GH treatment. GH treatment significantly improved neurologic symptoms in PASC patients but cognition, sleep, and physical performance were not significantly altered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormonePost-Acute COVID-19 SyndromeAdultAgedFemaleHumansMaleMiddle AgedBody CompositionCOVID-19FatiguePilot ProjectsQuality of LifeSARS-CoV-2Treatment Outcome

Substanzen

Human Growth Hormone

Autor:innen und Institutionen

  • Department of Internal Medicine, The University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Pediatrics, The University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Neurology, The University of Texas Medical Branch, Galveston, Texas, USA.
  • Centre for Neuro Skills, Bakersfield, California, USA.

ORCID-Profile: Traver J Wright, Melinda Sheffield-Moore, Richard B Pyles, Kathleen M Randolph, Kristen A McGovern, Christopher P Danesi, Mohammed F Zaidan, Randall J Urban

Förderung

  • NCATS NIH HHS

Zitieren

APA

Wright, T. J., Sheffield-Moore, M., Pyles, R. B., Randolph, K. M., McGovern, K. A., Danesi, C. P., Lindsay, S. E., Zaidan, M. F., Masel, B. E., & Urban, R. J. (2024). Growth hormone treatment for neurologic symptoms of post‐acute sequelae of COVID‐19. Clinical and Translational Science. https://doi.org/10.1111/cts.13826

Vancouver

Wright TJ, Sheffield-Moore M, Pyles RB, Randolph KM, McGovern KA, Danesi CP, et al. Growth hormone treatment for neurologic symptoms of post‐acute sequelae of COVID‐19. Clinical and Translational Science. 2024. doi:10.1111/cts.13826

BibTeX
@article{Wright2024,
  author = {Wright, Traver J and Sheffield-Moore, Melinda and Pyles, Richard B and Randolph, Kathleen M and McGovern, Kristen A and Danesi, Christopher P and Lindsay, Sarah E and Zaidan, Mohammed F and Masel, Brent E and Urban, Randall J},
  title = {Growth hormone treatment for neurologic symptoms of post‐acute sequelae of COVID‐19},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13826}
}
Kostenlos starten →